Kyntra Bio returns to profit in Q3 as revenue rises
KYNB•Kyntra Bio reported $157,000 in Q3 net income from continuing operations and $1.76 million in revenue from continuing operations. It restructured a royalty financing agreement, reducing maximum payment obligations by $60 million.
1. Q3 results
Kyntra Bio reported $157,000 in net income from continuing operations for the third quarter, reversing a loss a year earlier. Revenue from continuing operations was $1.76 million and rose year over year.
2. Pipeline and costs
The company discontinued development of FG-3246 and FG-3180 after interim analysis showed insufficient efficacy. It expects the terminations to help reduce operating expenses by more than $20 million in 2027 and 2028.
3. Financing and outlook
Kyntra Bio restructured its royalty financing agreement, reducing its maximum aggregate payment obligation by $60 million and leaving $15 million in future royalty-backed payments. It plans to begin a Phase 3 roxadustat trial in patients with LR-MDS in the first quarter of 2027, pending a partnership or capital raise, and expects cash and equivalents to fund operations into 2028.




